Cervix BT - 2016

Next generation of clinical trials based on IGABT + IGRT as RCT - Hypothesis driven -

 Comparative Trials on IGABT vs. 2D (randomized)  Dose escalation for advanced disease HR CTV (LC, OS)  Dose de-escalation for limited and favourable advanced disease (good response,…) (Morb/QoL)  Para-aortic RT, Lymphnode Boost (NC, OS)  Systematic concomitant radiochemotherapy min. 5 cycl for subgroups with high risk of distant metastases (OS)  Testing Dose/Volume constraints for Target and OARs  Biomarker investigation (Hypoxia, HPV, EGFR, VEGF..)